Yuki Kagoya1,2, Mineo Kurokawa1, Arrowsmith Cheryl2, Naoto Hirano2 (1.Dept. of Hematology and Oncology, University of Tokyo, Tokyo, Japan, 2.Princess Margaret Cancer Centre, Toronto, Canada)
Session information
Oral Session
Oral Session 1-11B Basic and clinical studies for immunotherapy
Fri. Oct 12, 2018 10:10 AM - 11:10 AM No.11 (Osaka International Convention Center, 10F 1004-5)
Chair: Norimitsu Kadowaki (Faculty of Medicine, Kagawa University, Japan)
Kisa Tanabe1, Takakazu Kawase1, Kazutaka Kitaura2, Takahiko Miyama2, Misaki Kobayashi2, Mayu Sato2, Takayuki Oda2, Aoi Sakamoto2, Kiyoto Tanaka2, Kiyotaka Kuzushima3, Kazuo Yamashita6, Tadasu Shin-I4, Ryuji Suzuki5, Tatsuo Ichinohe1 (1.Dept., Hematol. Oncol., Radi. Biol. Med., Hiroshima Univ., Hiroshima, Japan, 2.Repertoire Genesis Incorporation, Ibaraki, Japan, 3.Department of Immunology, Aichi Cancer Center Research Institute, 4.BITS Co. Ltd., Tokyo, Japan, 5.National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, 6.KOTAI Biotechnologies, Inc., Suita, Japan)
Tadahiro Honda1, Miki Ando1,2, Yumi Sakiyama2, Hayato Murakoshi3, Jun Ando1, Masafumi Takiguchi3, Hiromitsu Nakauchi2,4, Norio Komatsu1 (1.Department of Hematology, Juntendo University School of Medicine, 2.Division of Stem Cell Therapy, IMSUT, Tokyo, 3.Center for AIDS Research, Kumamoto University, 4.Institute for Stem Cell Biology and Regenerative Medicine, Stanford University)
Ryo Ishino1,2, Yumi Kawase1, Toshio Kitawaki1, Naoshi Sugimoto2,3, Yasushi Ino4, Tomoki Todo4, Akifumi Takaori-Kondo1, Norimitsu Kadowaki2 (1.Department of Hematology and Oncology, Kyoto Univ., Kyoto, Japan., 2.Division of Hematology, Rheumatology and Respiratory, Kagawa University, Kagawa, Japan., 3.CiRA., Kyoto University, Kyoto, Japan., 4.Division of Innovative Cancer Therapy, IMSUT, Tokyo, Japan.)
Ryo Hanajiri1, Michael Keller1, Patrick Hanley1, Esper Kallas2, Catherine Bollard1 (1.Children's National Medical Center, Washington DC, USA, 2.University of Sao Paulo, Sao Paulo, Brazil)
Youko Suehiro1, Tetsuya Fukuda2, Motoaki Shirathuchi3, Tadafumi Iino4, Atsuhiko Hasegawa5, Jun-Ichiro Yasunaga6, Akie Hirata7, Hayato Utsunomiya1, Hirofumi Ohno1, Takashi Ishida8, Koichi Akashi9, Masao Matsuoka10, Mari Kannagi5 (1.Department of Cell Therapy, National Kyushu Cancer Center, Fukuoka, Japan, 2.Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan, 3.Department of Medicine and Bioregulatory Science,Kyushu University, Fukuoka, Japan, 4.Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan, 5.Department of Immunotherapeutics, Tokyo Medical and Dental University, Tokyo, Japan, 6.Laboratory of Virus Control, Kyoto University, Kyoto, Japan, 7.Department of Clinical Laboratory, National Kyushu Cancer Center, Fukuoka, Japan, 8.Division of Hematology and Oncology, Iwate Medical University, Iwate, Japan, 9.Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan, 10.Department of Hematology, Kumamoto University, Kumamoto, Japan)